| Autor: |
TIAN Xi, XU Wenhao, ZHU Shuxuan, AIHETAIMUJIANG•Anwaier, SU Jiaqi, YE Shiqi, QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei |
| Jazyk: |
English<br />Chinese |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Zhongguo aizheng zazhi, Vol 33, Iss 3, Pp 191-200 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1007-3639 |
| DOI: |
10.19401/j.cnki.1007-3639.2023.03.001 |
| Popis: |
Renal cell carcinoma (RCC) is one of the three major urinary system tumors. With the changes of lifestyle and the rise of obesity, hypertension and other diseases, the incidence of RCC is increasing. The onset of RCC is hidden, and RCC has strong heterogeneity. Most RCC patients are found accidentally by imaging examination, so many patients were diagnosed in the advanced stage. Although the emergence of targeted therapy and immunotherapy has greatly prolonged the survival time of patients with advanced RCC, due to many pathological types of RCC, it is still difficult for many patients to benefit from the systematic treatment. Many basic and clinical studies are devoted to the development of new targets or drugs to prolong the survival time of patients. This article reviewed the advances in the research, diagnosis and treatment of RCC in 2022. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
